+86-400-890-9989
Product Catalog
> HVEM / TNFRSF14 Protein HVEM / TNFRSF14 Protein
Herpesvirus Entry Mediator/Tumor Necrosis Factor Receptor Superfamily, member 14
HVEM / TNFRSF14 Products
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| HVEM/TNFRSF14 | Human | HVEM/TNFRSF14/Fc Protein, Recombinant |
10334-H03H |
| HVEM/TNFRSF14 | Human | HVEM/TNFRSF14 Protein, Recombinant | 10334-H08H |
| HVEM/TNFRSF14 | Mouse | HVEM/TNFRSF14/Fc Protein, Recombinant | 10567-M03H |
| Molecule | Species | Description //For Detailed Info. and Price------CLICK! | Cat. No |
| HVEM/TNFRSF14 | Human | Homo sapiens HVEM/TNFRSF14 cDNA Clone(NM_003820.2) | HG10334-M |
| HVEM/TNFRSF14 | Mouse | Mus musculus HVEM/TNFRSF14 cDNA Clone | MG50550-M |
| HVEM/TNFRSF14 | Cynomolgus | Cynomolgus monkey TNFRSF14 cDNA Clone / ORF Clone | KG90109-G |
HVEM / TNFRSF14 Related Areas
Immunology>>Adaptive Immunity>>B Cell>>HVEM/TNFRSF14
Immunology>>Adaptive Immunity>>Costimulation & Costimulatory Molecule>>HVEM/TNFRSF14
Immunology>>Cytokine & Receptor>>TNF Superfamily>>HVEM/TNFRSF14
Immunology>>Innate Immunity>>Monocyte/Macrophage>>Monocyte Marker>>HVEM/TNFRSF14
HVEM / TNFRSF14 Alternative Names
HVEM, TNFRSF14, HVEA, RP3-395M20.6, ATAR, LIGHTR, TR2 [Homo sapiens]
Hvem, Tnfrsf14, HveA, RP24-89N4.1, Atar, MGC123498, MGC123499, Tnfrs14 [Mus musculus]
HVEM / TNFRSF14 Related Products
Antibody Products
| Molecule | Application | Description //For Detailed Info. and Price------CLICK! |
| Human TNFRSF1B/TNFR2/CD120b |
WB, ELISA | Rabbit Polyclonal Antibody |
| Human TNFRSF1B/TNFR2/CD120b |
WB, ELISA | Rabbit Polyclonal Antibody (Antigen Affinity Purified) |
| Human TNFRSF5/CD40 |
WB, ELISA | Rabbit Polyclonal Antibody |
| Human TNFRSF5/CD40 |
WB, ELISA | Rabbit Polyclonal Antibody (Antigen Affinity Purified) |
| Human TNFRSF10B/CD262/ TRAILR2 |
WB, ELISA | Rabbit Polyclonal Antibody |
| Human TNFRSF10B/CD262/ TRAILR2 |
WB, ELISA | Rabbit Polyclonal Antibody (Antigen Affinity Purified) |
HVEM / TNFRSF14 Background
Herpesvirus entry mediator (HVEM), also referred to as TNFRSF14, TR2 (TNF receptor-like molecule) and ATAR (another TRAF-associated receptor), is a member of type I transmembrane protein belonging to the TNF-receptor superfamily. It is expressed on many immune cells, including T and B cells, NK cells, monocytes, and neutrophils. Two TNF superfamily ligands lymphotoxin α (TNF-β) and LIGHT (TNFSF14) are identified as cellular ligands for HVEM and initiate the positive signaling. However, recent studies have revealed that HVEM is also involved in the unique inhibitory signaling pathway for T cells through activating tyrosine phosphorylation of the immunoreceptor tyrosine-based inhibitory motif (ITIM) in B and T lymphocyte attenuator (BTLA). HVEM provides a stimulatory signal following engagement with LIGHT (TNFSF14) on T cells. In contrast, it can also provide an inhibitory signal to T cells when it binds the B and T lymphocyte attenuator (BTLA), a ligand member of the Immunoglobulin (Ig) superfamily. Thus, HVEM may be viewed as a molecular switch, capable of facilitating both stimulatory and inhibitory cosignaling in T cells. Substantial evidence from both human disease and from experimental mouse models has indicated that dysregulation of the LIGHT-HVEM-BTLA cosignaling pathway can cause inflammation in the lung and in mucosal tissues.
HVEM / TNFRSF14 Related Studies
- Murphy KM, et al. (2006) Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol. 6(9): 671-81.
- Heo SK, et al. (2007) HVEM signaling in monocytes is mediated by intracellular calcium mobilization. J Immunol. 179(9): 6305-10.
- Steinberg MW, et al. (2008) A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med. 205(6): 1463-76.
- Pasero C, et al. (2009) A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production. Eur J Immunol. 39(9): 2502-14.
- Cheung TC. Modulation of T cell proliferation through the LIGHT-HVEM-BTLA cosignaling pathway. Recent Pat DNA Gene Seq. 3(3): 177-82.
